Corporate Action23 Sept 2026, 05:11 pm
Concord Biotech Approves 1:1 Bonus Issue & Capital Increase
AI Summary
Concord Biotech Limited's Board of Directors has approved a 1:1 bonus share issuance, meaning one bonus share for every one held, capitalized from the share premium account. Additionally, the company will increase its authorized share capital from ₹11 crore to ₹22 crore by creating 11 crore new equity shares. Both proposals are subject to shareholder approval. The board meeting was held on September 23, 2026.
Key Highlights
- Board approves 1:1 bonus share issuance.
- Authorized share capital to double from ₹11 Cr to ₹22 Cr.
- Bonus shares to be issued from share premium account.
- Both proposals require shareholder approval.
- Record date for bonus issue to be determined by the Board.
Price Impact
More from CONCORDBIO